menu
    • menu

    Company profile for Aspen Pharmacare Holdings

    NEW Drugs in Dev: 11
    Aspen API-PSE
    News
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion

    29 Dec 2025

    // PRESS RELEASE

    Stephen Saad receives both AABLA Lifetime Achievement Award

    13 Nov 2025

    // PRESS RELEASE

    Aspen Highlights Rising Diabetes Disease Burden

    13 Nov 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Aspen API

    Contact Supplier

    Website

    International Sweetener Colloquium

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/fda-s-december-2025-opoe-list-features-784-prescription-drugs-73-otc-drugs

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen is represented in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aspen Pharmacare HoldingsSouthAfrica Flag
    Country
    Country
    South Africa
    Address
    Address
    Aspen House, Aspen Park 98 Armstrong Avenue La Lucia Ridge, Durban
    Telephone
    Telephone
    +27 315808600
    Client Email
    Email
    jkemmeren@nl.aspenpharma.com
    Client Website
    Website
    https://www.aspenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aspen-pharmacare-global/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/aspenpharma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4469

    https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities

    #PharmaFlow by PHARMACOMPASS
    22 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion

    29 Dec 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/proposed-divestment-of-aspen-asia-pacific-excluding-china-for-r26-5-billion/

    PRESS RELEASE
    29 Dec 2025
    Share Share
    Stephen Saad receives both AABLA Lifetime Achievement Award
    Stephen Saad receives both AABLA Lifetime Achievement Award

    13 Nov 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/stephen-saad-aabla-2025/

    PRESS RELEASE
    13 Nov 2025
    Share Share
    Aspen Highlights Rising Diabetes Disease Burden
    Aspen Highlights Rising Diabetes Disease Burden

    13 Nov 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-wdd-2025/

    PRESS RELEASE
    13 Nov 2025
    Share Share
    Aspen Wins Approval to Market Lilly's Mounjaro in South Africa
    Aspen Wins Approval to Market Lilly's Mounjaro in South Africa

    13 Oct 2025

    // REUTERS

    https://www.reuters.com/sustainability/boards-policy-regulation/aspen-wins-approval-market-lillys-mounjaro-weight-loss-south-africa-2025-10-13/

    REUTERS
    13 Oct 2025
    Share Share
    Aspen Aims for Profit Turnaround with Insulin, GLP-1 Drugs
    Aspen Aims for Profit Turnaround with Insulin, GLP-1 Drugs

    04 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/south-africas-aspen-aims-profit-turnaround-with-insulin-glp-1-drugs-2025-09-03/

    REUTERS
    04 Sep 2025
    Share Share
    Aspen building momentum in Commercial Pharma & Manufacturing
    Aspen building momentum in Commercial Pharma & Manufacturing

    03 Sep 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-building-momentum-in-commercial-pharmaceuticals-and-manufacturing-strategy-modified/

    PRESS RELEASE
    03 Sep 2025
    Share Share

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine

    Aspen Pharmacare Holdings

    Dosage Form : Salve

    Brand Name : Xylocain

    Dosage Strength : 0.05

    Packaging :

    Approval Date : 23-11-1949

    Application Number : 1.95E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine

    Aspen Pharmacare Holdings

    Dosage Form : Cutaneous Spray

    Brand Name : Xylocain

    Dosage Strength : 100mg/ml

    Packaging :

    Approval Date : 26-11-1990

    Application Number : 1.99E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Injectable Solution

    Brand Name : Xylocain

    Dosage Strength : 20mg/ml

    Packaging :

    Approval Date : 20-07-1949

    Application Number : 1.95E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Injectable Solution

    Brand Name : Xylocain

    Dosage Strength : 5mg/ml

    Packaging :

    Approval Date : 31-05-1951

    Application Number : 1.95E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Injectable Solution

    Brand Name : Xylocain

    Dosage Strength : 10mg/ml

    Packaging :

    Approval Date : 31-05-1951

    Application Number : 1.95E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Xylocain

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Gel

    Brand Name : Xylocain

    Dosage Strength : 0.02

    Packaging :

    Approval Date : 02-01-1953

    Application Number : 1.95E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Xylocain Visk?s

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Oral Solution

    Brand Name : Xylocain Visk?s

    Dosage Strength : 20mg/ml

    Packaging :

    Approval Date : 28-06-1954

    Application Number : 1.95E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Xylocain Utan Konser...

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Gel

    Brand Name : Xylocain Utan Konserverin...

    Dosage Strength : 0.02

    Packaging :

    Approval Date : 29-08-1986

    Application Number : 1.99E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Xylocain Utan Konser...

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Injectable Solution

    Brand Name : Xylocain Utan Konserverin...

    Dosage Strength : 10mg/ml

    Packaging :

    Approval Date : 08-05-1987

    Application Number : 1.99E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Xylocain Utan Konser...

    South Africa
    arrow
    BioAsia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Lidocaine Hydrochloride Monohydrate

    Aspen Pharmacare Holdings

    Dosage Form : Injectable Solution

    Brand Name : Xylocain Utan Konserverin...

    Dosage Strength : 20mg/ml

    Packaging :

    Approval Date : 11-12-1987

    Application Number : 1.99E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search